RBC Capital analyst Brian Abrahams maintained a Hold rating on Biogen Inc (NASDAQ:BIIB) on Wednesday, setting a price target of $263, which is approximately 2.20% below the present share price of $268.91.
Abrahams expects Biogen Inc to post earnings per share (EPS) of $9.60 for the fourth quarter of 2020.
The current consensus among 20 TipRanks analysts is for a Moderate Buy rating of shares in Biogen, with an average price target of $298.13.
The analysts price targets range from a high of $357 to a low of $235.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $3.68 billion and a net profit of $1.98 billion. The company's market cap is $42.57 billion.
According to TipRanks.com, RBC Capital analyst Brian Abrahams is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.2% and a 47.99% success rate.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp (OTC:SHCAY) in 1978 and is headquartered in Cambridge, MA.